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Abstract
This article is part of a series written for people responsible for making decisions about health policies and
programmes and for those who support these decision makers.
Policy briefs are a relatively new approach to packaging research evidence for policymakers. The
first step in a policy brief is to prioritise a policy issue. Once an issue is prioritised, the focus then
turns to mobilising the full range of research evidence relevant to the various features of the issue.
Drawing on available systematic reviews makes the process of mobilising evidence feasible in a way
that would not otherwise be possible if individual relevant studies had to be identified and
synthesised for every feature of the issue under consideration. In this article, we suggest questions
that can be used to guide those preparing and using policy briefs to support evidence-informed
policymaking. These are: 1. Does the policy brief address a high-priority issue and describe the
relevant context of the issue being addressed? 2. Does the policy brief describe the problem, costs
and consequences of options to address the problem, and the key implementation considerations?
3. Does the policy brief employ systematic and transparent methods to identify, select, and assess
synthesised research evidence? 4. Does the policy brief take quality, local applicability, and equity
considerations into account when discussing the synthesised research evidence? 5. Does the policy
brief employ a graded-entry format? 6. Was the policy brief reviewed for both scientific quality and
system relevance?
About STP
This article is part of a series written for people responsible for
making decisions about health policies and programmes and for
those who support these decision makers. The series is intended
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to help such people ensure that their decisions are well-informed
by the best available research evidence. The SUPPORT tools
and the ways in which they can be used are described in more
detail in the Introduction to this series [1]. A glossary for the
entire series is attached to each article (see Additional File 1).
Links to Spanish, Portuguese, French and Chinese translations
of this series can be found on the SUPPORT website http://
www.support-collaboration.org. Feedback about how to
improve the tools in this series is welcome and should be sent to:
STP@nokc.no.
Scenarios
Scenario 1: You are a senior civil servant and have been sent a
policy brief that describes the research evidence about an issue
that is of growing concern to the Minister. You are responsible
for ensuring that the policy brief profiles research evidence in a
way that informs different elements of the issue and recognises
the importance of drawing on both local and global evidence.
You want to ensure that the policy brief won't place the Minister
in an awkward position by making a recommendation that is
not politically or economically feasible.
Scenario 2: You work in the Ministry of Health and have been
given a few hours to prepare an assessment of a policy brief that
has been sent to the Ministry on a high-priority issue. All that
you have been told is that this policy brief is different in a
number of ways to the type of policy brief that you have pro-
duced in the past including the way in which it profiles research
evidence about a problem, the options and implementation con-
siderations, and the fact that it does not conclude with a specific
recommendation.
Scenario 3: You work in an independent unit that supports the
Ministry of Health in its use of research evidence in policymak-
ing. You are preparing a policy brief for both the Ministry and
key stakeholders to profile what is known and not known about
a problem, options for addressing it, and implementation con-
siderations. You have been told to prepare the brief in a system-
atic way and to report the methods and findings in a
transparent and readily understandable way, but you want
guidance on how to be both thorough and efficient in your
work.
Background
For policymakers (Scenario 1), this article suggests a
number of questions that they might ask themselves or
their staff to consider when assessing a policy brief. For
those who support policymakers (Scenarios 2 and 3), this
article suggests a number of questions to guide the assess-
ment of a policy brief or the preparation of one.
Three major shifts have occurred recently in the focus of
many efforts to package research evidence for policymak-
ers. Firstly, there has been a shift from packaging single
studies to packaging systematic reviews of studies that
address typical policy-relevant questions. A number of
research groups, including the SUPPORT collaboration
http://www.support-collaboration.org/, now produce
policymaker-friendly summaries of systematic reviews.
These summaries always highlight the key messages from
the review but some of them, like SUPPORT summaries,
also address considerations related to quality, local appli-
cability, and equity [2]. This shift has made it easier for
policymakers to scan broadly across large bodies of
research evidence. And it has also enabled them to extract
what they need to know easily from particular systematic
reviews that directly address key features of any policy
issue of interest.
Secondly, there have been more recent complementary
efforts to package systematic reviews (together with local
research evidence) in the form of a new product - the pol-
icy brief - which mobilises the best available research evi-
dence on high-priority issues [3]. For policy briefs, the
starting point is the issue and not the related research evi-
dence that has been produced or identified. Once an issue
is prioritised, the focus then turns to mobilising the full
range of research evidence addressing the different fea-
tures of the issue concerned. These include the underlying
problem, options to address the problem, and key imple-
mentation considerations. Drawing on available system-
atic reviews makes the process of evidence mobilisation
feasible in a way that would not otherwise be possible if
single studies had to be identified and synthesised for all
the features of the issue. In this article, we have restricted
our use of the term 'policy brief' to those products match-
ing this description exactly. But the term has also been
applied elsewhere to many other types of products pre-
pared by those supporting policymakers. The appropria-
tion of this term by those involved in producing and
supporting the use of research evidence reflects perhaps
their increasing orientation to the needs and contexts of
policymakers.
Evidence-packaging mechanisms and policy briefs in par-
ticular have been developed largely as a response to the
findings of systematic reviews of factors influencing the
use of research evidence in policymaking [4,5]. Three fac-
tors in particular have emerged as significant. These are: 1.
Timing or timeliness, 2. Accordance between the research
evidence and the beliefs, values, interests, or political
goals and strategies of policymakers and stakeholders,
and 3. Interactions between researchers and policymakers.
Having access to both a stock of the summaries of system-
atic reviews and policy briefs helps to address the need
that policymakers have for timely inputs to policymaking
processes [6]. Review summaries and policy briefs can typ-
ically be produced in days and weeks rather than the
months or years required to prepare a systematic reviewHealth Research Policy and Systems 2009, 7(Suppl 1):S13 http://www.health-policy-systems.com/content/7/S1/S13
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from scratch. Undertaking primary research (i.e. original
studies) can be similarly and often more time intensive.
Evidence-packaging mechanisms, and policy briefs in par-
ticular, can also make it easier for policymakers and other
stakeholders to determine whether and how the available
research evidence accords with their own beliefs, values,
interests, or political goals and strategies. With a problem
clarified, what is known and not known about the options
clearly described, and key implementation considerations
clearly flagged, policymakers may be more readily able to
identify viable ways forward.
Thirdly, changes have occurred in the purpose for which
packaged research evidence has typically been produced.
Policy briefs are increasingly used as an input into policy
dialogues involving individuals drawn from those who
will be involved in, or affected by, decisions about a par-
ticular issue. These dialogues provide the opportunity for
greater interaction between researchers and policymakers.
Dialogues in which research evidence is just one input in
a policy discussion form the focus of Article 14 in this
series [7].
The formats used for evidence-packaging have often been
developed in response to the few available empirical stud-
ies of the preferences of health policymakers for different
kinds of mechanisms (and not their usage or effects, which
typically have not been evaluated) [4,8]. These studies
have revealed a need amongst policymakers to have for-
mats that both provide graded entry to the full details of a
review and facilitate assessment of decision-relevant infor-
mation [4]. A graded-entry format of one page of take-
home messages, a three-page executive summary that
summarises the full report, and a 25-page report (i.e. a
1:3:25 format) has shown to be particularly promising
[9]. Presumably, either the one- or three-page summary
should follow a structured format [10]. Structured
abstracts have been found to have an effect on intermedi-
ate outcomes such as searchability, readability and recall
among healthcare providers. However, no studies have
compared full text to structured abstracts and no studies
have examined the impact of format features on policy-
makers [11]. Decision-relevant information can include
the important impacts (both benefits and harms) and
costs (i.e. resources used) of policy and programme
options, as well as local applicability and equity consider-
ations [4].
Questions to consider
The following questions can be used to guide the prepara-
tion and use of policy briefs to support evidence-informed
policymaking:
1. Does the policy brief address a high-priority issue and
describe the relevant context of the issue being addressed?
2. Does the policy brief describe the problem, costs and
consequences of options to address the problem, and the
key implementation considerations?
3. Does the policy brief employ systematic and transpar-
ent methods to identify, select, and assess synthesised
research evidence?
4. Does the policy brief take quality, local applicability,
and equity considerations into account when discussing
the research evidence?
5. Does the policy brief employ a graded-entry format?
6. Was the policy brief reviewed for both scientific quality
and system relevance?
1. Does the policy brief address a high-priority issue and 
describe the relevant context of the issue being addressed?
Policy briefs are distinguished most clearly from other
packaged evidence summaries by the fact that they begin
with the explicit identification of a high-priority issue. In
instances where an issue has been on the agenda of key
stakeholders for some time, policy briefs may act as a way
to spur progress. This is highlighted in the example shown
in Table 1 of low coverage rates for artemisinin-based
combination therapies (ACT) to treat uncomplicated fal-
ciparum malaria in sub-Saharan African countries. Alter-
natively, if the issue is relatively new, the policy brief may
play an agenda-setting role. Either way, it is critical that
the issue is deemed a priority by at least some key stake-
holders. Ideally the prioritisation process should also be
systematic and transparent and Article 3 in this series out-
lines an approach for achieving this [12].
A second key feature of policy briefs is that they are typi-
cally context-specific. Describing the key features of a con-
text in the policy brief is important as a way of creating a
level playing field among policy brief readers. Table 2
highlights issues related to limited or inequitable access to
sustainable, high-quality community-based primary
healthcare in Canada. There, as the policy brief explained,
the issue could only be understood in the context of the
particular features of Canadian primary healthcare and
the existence of 'private delivery/public payment' arrange-
ments with physicians. These are of particular importance
in this context for they have meant historically that most
primary healthcare in Canada is delivered by physicians
working in private practice with first-dollar, public (typi-
cally fee-for-service) payment [13]. Improving access in
creative ways, including the use of collaborative practice
models, requires an understanding that: 1. Physicians
tend to be wary of potential infringements on their profes-
sional and commercial autonomy, 2. No other healthcare
providers at this time can secure the public paymentHealth Research Policy and Systems 2009, 7(Suppl 1):S13 http://www.health-policy-systems.com/content/7/S1/S13
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required to function independently as primary healthcare
providers on a viable scale, and 3. Many forms of care
(including prescription drugs and home care services)
would still not be covered [14].
2. Does the policy brief describe the problem, costs and 
consequences of options to address the problem, and the 
key implementation considerations?
A policy brief would ideally describe different features of
a problem, what is known (and not known) about the
costs and consequences of options for addressing the
problem, and key implementation considerations. As out-
lined in Article 4, a problem can be understood in one or
more of the following terms [15]:
1. The nature and burden of the actual common diseases
and injuries that the healthcare system must prevent or
treat
2. The cost-effective programmes, services and drugs that
are needed for prevention and treatment, and
3. The broader health system arrangements that deter-
mine access to, and the use of, cost-effective programmes,
services and drugs, including how they affect particular
groups.
A policy brief would help to clarify the problem by diag-
nosing it in one or more of these terms.
Ideally, the number of options described in a brief that is
to be presented to senior policymakers would conform to
local document conventions. Three-option models, for
instance, are familiar to many policymakers. But regard-
less of the number selected, each option in the policy brief
can be characterised in terms of:
• The benefits of each option
Table 1: Outline of a policy brief about supporting the widespread use of a new, highly effective treatment for malaria in an African 
country
What problem has been identified?
• The overarching problem is one of low coverage rates for artemisinin-based combination therapies (ACT) to treat uncomplicated falciparum 
malaria in sub-Saharan Africa. Key features of the problem include:
• A high incidence of, and death rates from, malaria
• Existing treatments have much lower cure rates than ACT. However, patients often favour existing treatments because of their past 
experiences and the higher price of ACT
• The national malaria control policy, treatment guidelines, and drug formulary in many countries do not all support the prescription, dispensing 
and use of ACT
• Delivery arrangements for ACT often rely primarily on physicians but not everyone has regular access to them and many are comfortable 
receiving care from community health workers. Financial arrangements favour existing treatments over ACT (which is much more expensive) 
yet some patients are sceptical about heavily subsidised medication. Governance arrangements often do not allow community health workers to 
prescribe ACT and do not protect against counterfeit or substandard drugs
What information do systematic reviews provide about three viable options to address the problem?
• Each of the following three options was assessed in terms of the likely benefits, harms, costs (and cost-effectiveness), key elements of the policy 
option if it was tried elsewhere, and the views and experiences of relevant stakeholders:
• Enlarge the scope of practice for community health workers to include the diagnosis of malaria and prescription of ACT (governance 
arrangements), introduce target payments for achieving a defined coverage rate for ACT treatment (financial arrangements), and provide them 
with training and supervision for the use of both rapid diagnostic tests and prescribing (delivery arrangements)
• Introduce partial subsidies for both rapid diagnostic tests and ACT within the private sector where much care is provided in urban areas 
(financial arrangements)
• Restrict the types of anti-malaria drugs that can be imported and introduce penalties for those found dispensing counterfeit or substandard 
drugs (governance arrangements) and make changes to the national malaria control policy and drug formulary to ensure that ACT is the 
recommended first-line treatment
• Important uncertainties about each option's benefits and potential harms were flagged in order to give them particular attention as part of any 
monitoring and evaluation plan put into place
What key implementation considerations need to be borne in mind?
• A number of barriers to implementation were identified, among which were the familiarity of some patients and healthcare providers with existing 
treatment options and their resistance to change. Systematic reviews about the effects of mass media campaigns, the effects of strategies for 
changing healthcare provider behaviour generally, and for influencing prescribing and dispensing specifically, all proved helpful in deciding how to 
address these barriers
Notes about the supporting evidence base:
• Six systematic reviews about anti-malarial drugs had been published since the release of the World Health Organization guidelines in 2006, all of 
which lent further support to ACT as the recommended first-line treatment
• Of the systematic reviews identified: two addressed relevant governance arrangements, six addressed financial arrangements, five addressed 
specific configurations of human resources for health, and fifteen addressed implementation strategies, many of which could be supplemented by 
local studiesHealth Research Policy and Systems 2009, 7(Suppl 1):S13 http://www.health-policy-systems.com/content/7/S1/S13
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￿ The harms of each option
￿ The costs of each option or their relative cost-effective-
ness (if possible)
￿ The degree of uncertainty related to these costs and con-
sequences (so that monitoring and evaluation can focus
on particular areas of uncertainty if any given option is
pursued)
￿ Key elements of the policy option if it has been tried
elsewhere and adaptation is being considered, and
￿ Stakeholder views about and experiences with each
option
A policy brief would help to make clear the trade-offs
involved in selecting one option over others. If the
options are not designed to be mutually exclusive, a policy
brief would also help to make clear the benefits of com-
bining particular elements of the different options and
which combination of options might bring about positive
synergies. Alternatively, the elements from one or more
individual options could be presented first, followed by
'bundles' of options combining different elements in var-
ious ways.
Barriers to implementation (outlined in further detail in
Article 6 in this series) are located at different levels, rang-
ing from the consumer (citizen or healthcare recipient)
level through to healthcare providers, organisations, and
broader systems [16]. Policy briefs would help to identify
Table 2: Outline of a policy brief about improving access to high quality primary healthcare in Canada
What problem has been identified?
• The problem is limited or inequitable access to sustainable, high-quality community-based primary healthcare in federal, provincial, and territorial 
publicly-funded health systems in Canada. Key characteristics of the problem include:
• Chronic diseases represent a significant share of the common conditions that must be prevented or treated by the primary healthcare system
• Access to cost-effective programmes, services and drugs in Canada is not ideal. This is the case both when Canadians identify their own care 
needs or (more proactively on the part of healthcare providers) when they have an indication (or need) for prevention or treatment, particularly 
for chronic disease prevention and treatment
• Health system arrangements have not always supported the provision of cost-effective programmes, services and drugs. Many Canadians do 
not:
1. Have a regular physician or place of care
2. Receive effective chronic-disease management services, or
3. Receive care in a primary healthcare practice that uses an electronic health record, faces any financial incentive for quality, or provides nursing 
services
What is more difficult to determine is the proportion of physicians who receive effective continuing professional development for chronic disease 
management and the proportion of primary healthcare practices that:
1. Are periodically audited for their performance in chronic disease management
2. Employ physician-led or collaborative practice models, and
3. Adhere to a holistic primary healthcare model's (the Chronic Care Model's) key features [21]
What information do systematic reviews provide about three viable options to address the problem?
• Each of the following three options was assessed in terms of its likely benefits, harms, costs (and cost-effectiveness), its key elements if it had been 
tried elsewhere, and stakeholder views about and experiences with it:
• Support the expansion of chronic disease management in physician-led care through a combination of electronic health records, target 
payments, continuing professional development, and auditing of their primary healthcare practices
• Support the targeted expansion of inter-professional, collaborative practice primary healthcare
• Support the use of the Chronic Care Model in primary healthcare settings. This model entails the combination of self-management support, 
decision support, delivery system design, clinical information systems, health system, and community
• Important uncertainties about each option's benefits and potential harms were flagged. This was done in order to give these issues particular 
attention within any monitoring and evaluation plan put into place
What key implementation considerations need to be borne in mind?
• Little empirical research evidence could be identified about implementation barriers and strategies. Four of the implementation barriers identified 
were:
1. Initial wariness amongst some patients of potential disruptions to their relationship with their primary healthcare physician
2. Wariness on the part of physicians (particularly older physicians) of potential infringements on their professional and commercial autonomy
3. The organisational scale required for some of the options is not viable in many rural and remote communities, and
4. Hesitancy on the part of governments about broadening the breadth and depth of public payment for primary healthcare, particularly during a 
recession
Notes about the supporting evidence base:
• Dozens of relevant systematic reviews were identified, some of which addressed an option directly and others of which addressed elements of 
one or more options [14]Health Research Policy and Systems 2009, 7(Suppl 1):S13 http://www.health-policy-systems.com/content/7/S1/S13
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these barriers and describe what can reasonably be
expected (again, in terms of benefits, harms, and costs) as
a result of pursuing alternative implementation strategies
to address these barriers. A policy brief could also identify
considerations related to the preparation of a monitoring
and evaluation plan. Table 3 provides a possible outline
for a policy brief.
3. Does the policy brief employ systematic and transparent 
methods to identify, select, and assess synthesised research 
evidence?
Policymakers and a wide range of stakeholders who will
be involved in or affected by a decision, are the main audi-
ence of a policy brief. Research language should therefore
be kept to a minimum as most people will be unfamiliar
with it. A policy brief, nevertheless, should still ideally
describe how synthesised research evidence was identi-
Table 3: Possible outline of a policy brief
Title (possibly in the form of a compelling question)
Key messages (possibly as bullet points)
• What is the problem?
• What do we know (and not know) about viable options to address the problem?
• What implementation considerations need to be borne in mind?
Report
• Introduction that describes the issue and the context in which it will be addressed
• Definition of the problem such that its features can be understood in one or more of the following terms:
1. The nature and burden of common diseases and injuries that the healthcare system must prevent or treat
2. The cost-effective programmes, services and drugs that are needed for prevention and treatment, and
3. The health system arrangements that determine access to and use of cost-effective programmes, services and drugs, including how they affect 
particular groups
• Options for addressing the problem, with each one assessed in a table (an example is shown below)
Category of finding Nature of findings from systematic reviews and other available 
research evidence
Benefits
Harms
Costs and cost-effectiveness
Uncertainty regarding benefits and potential harms
Key elements of the option (how and why it works)
Stakeholders' views and experiences
• Implementation considerations, with potential barriers to implementing the options assessed in a table (please see example below), each viable 
implementation strategy also assessed in table (please see example above), and suggestions for a monitoring and evaluation plan
Levels Option 1 Option 2 Option 3
Consumer
Healthcare provider
Organisation
System
Additional content that could appear on a cover page or in an appendix:
• A list of authors and their affiliations
• A list of those involved in establishing the terms of reference for the policy brief and their affiliations
• A list of key informants who were contacted to gain additional perspectives on the issue and to identify relevant data and research evidence, and 
their affiliations
• A list of funders (for the organisation producing the policy brief and for the policy brief itself)
• A statement about conflicts of interest among authors
Additional content that could appear in boxes or in an appendix
• Methods used to identify, select, and assess synthesised research evidence 
(including assessments of quality, local applicability and equity considerations)
• Review process used to ensure the scientific quality and system relevance of the policy briefHealth Research Policy and Systems 2009, 7(Suppl 1):S13 http://www.health-policy-systems.com/content/7/S1/S13
Page 7 of 9
(page number not for citation purposes)
fied, selected and assessed in ways that are easily under-
stood. This objective can be achieved by using techniques
such as explanatory 'boxes' within the brief to clarify or
highlight particular concepts, or through the inclusion of
additional appendices. The methods, too, should be sys-
tematic in nature and reported in a transparent yet under-
standable way. For example, users could be provided with
a description of how systematic reviews addressing the
benefits and harms of particular health system arrange-
ments were identified through a search of continuously
updated databases containing reviews in particular
domains. This could provide significant reassurance to
readers that most, if not all, key reviews had been found
and that few, if any, key reviews had been missed.
4. Does the policy brief take quality, local applicability, 
and equity considerations into account when discussing 
the research evidence?
Systematic reviews may be of high or low quality, their
findings may be highly applicable to a given policy-
maker's setting or of very limited applicability, and they
may or may not give consideration to the impacts an
option is likely to have on disadvantaged groups, and on
equity in a specific setting. Ideally, a policy brief would
flag such variations for policymakers and other readers. As
outlined in Article 8, explicit criteria are available to assist
with quality assessments [17]. Importantly, some data-
bases of systematic reviews, such as Rx for Change http://
www.rxforchange.ca, provide quality ratings for all
reviews contained in the database. If possible, a policy
brief would provide a quality review for all systematic
reviews from which key messages have been extracted.
Explicit criteria are also available to assist with local appli-
cability assessments and these are outlined in further
detail in Article 9 [18]. Given that policy briefs are typi-
cally context-specific, a policy brief would also ideally
comment on the local applicability of the findings of any
systematic reviews that are critical to an understanding of
the impacts of any options being considered. Equity con-
siderations can also be addressed using explicit criteria
(see Article 10) [19]. A policy brief should also note in its
introduction whether any groups have been given partic-
ular attention in the brief. Group-specific key messages
could be added to the overall key messages in each sec-
tion.
5. Does the policy brief employ a graded-entry format?
A policy brief would ideally allow busy policymakers and
other readers to scan the key messages quickly in order to
determine whether these corresponded sufficiently closely
to their key issue of concern and context to warrant read-
ing the entire document. A graded-entry format could take
a number of forms. These could be achieved, for example,
through a 1:3:25 format - i.e. one page of take-home mes-
sages, a three-page executive summary, and a 25page
report [9]. Or a brief may take the form of a 1:12 format,
with one page of take-home messages followed by a 12-
page report. Whatever form is chosen, the minimum that
a policy brief should contain is a list of key messages, a
report, and a reference list for those who wish to read
more. The key messages would range from the identifica-
tion of the problem through what is known about the
options, and the key considerations for implementation.
A number of other features of a policy brief could engage
potential readers and facilitate assessments of who was
involved in preparing, informing and funding it. The title
of a policy brief could be worded in a way that would
engage policymakers and other stakeholders. This could
be achieved, for example, by using a compelling question
as a title. The cover and/or the acknowledgements section
of a policy brief could provide a list of authors and their
affiliations. It could also include a list of those involved in
establishing the terms of reference of the policy brief, a list
of the key informants contacted for additional perspec-
tives on the issue and to identify relevant data and
research evidence, and their affiliations. A list of funders
for both the organisation producing the policy brief and
the policy brief itself, and a statement about any conflicts
of interest among authors could also form part of the pol-
icy brief document.
6. Was the policy brief reviewed for both scientific quality 
and system relevance?
Policy briefs need to meet two standards: scientific quality
and system relevance. To ensure this, the review process
could involve at least one policymaker, at least one other
stakeholder, and at least one researcher. This so-called
merit review process differs from a typical peer review proc-
ess that would typically only involve researchers in the
review process, and hence focus primarily on scientific
quality. Involving policymakers and other stakeholders
can help to ensure the brief's relevance to the health sys-
tem.
Conclusion
Policy briefs are a new approach to supporting evidence-
informed policymaking. Their preparation and use con-
tinues to evolve through practical experience. Evaluations
of this new approach are needed in order to improve our
understanding of which particular design features are well
received for particular types of issues and in particular
contexts. Describing the different features of a problem
may, for example, be perceived as being particularly
important for highly politicised topics where the very
nature of the problem is contentious. Taking equity con-
siderations into account through a focus on only one
group may be perceived as inappropriate in political sys-
tems that may have a long tradition of either addressing
all major ethnocultural groups in policy documents orHealth Research Policy and Systems 2009, 7(Suppl 1):S13 http://www.health-policy-systems.com/content/7/S1/S13
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perhaps of focusing on no groups in particular. Evalua-
tions are also necessary as a way of improving our under-
standing of whether, and how, policy briefs influence
policymaking. Table 4 provides a description of one
approach to the formative evaluation of policy briefs.
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munication Notes: Reader-Friendly Writing - 1:3:25.
Ottawa, Canada: Canadian Health Services Research
Foundation: http://www.chsrf.ca/knowledge_transfer/
pdf/cn-1325_e.pdf - Source of advice about writing for an
audience of policymakers and other stakeholders
- Lavis JN, Boyko JA: Evidence Brief: Improving Access to Pri-
mary Healthcare in Canada. Hamilton, Canada: McMaster
Health Forum; 2009 [14] - Example of a policy brief for a
specific country (Canada)
- Oxman AD, Bjorndal A, Flottorp SA, Lewin S, Lindahl
AK: Integrated Health Care for People with Chronic Condi-
tions. Oslo, Norway: Norwegian Knowledge Centre for the
Health Services; 2008 [20]: http://www.kunnskapssen
teret.no/Publikasjoner/5114.cms?threepage=1 - Example
of a policy brief that provides an exhaustive review of the
potential elements of policy options before bundling
them together into three viable options for a specific
country (Norway)
Links to websites
- Health Evidence Network/European Observatory on
Health Systems and Policies: http://www.euro.who.int/
hen/policybriefs/20070327_1 - Source of policy briefs tar-
geted at policymakers in the World Health Organization's
European Region
- Program in Policy Decision-Making (PPD)/Canadian
Cochrane Network and Centre (CCNC) database: http://
www.researchtopolicy.ca/search/reviews.aspx - Source of
policy briefs as well as systematic reviews and overviews of
systematic reviews (with links to policymaker-friendly
Table 4: An example of an approach to the formative evaluation of a policy briefs series
• The McMaster Health Forum surveys those to whom it sends a policy brief, with the long term goal of identifying which design features work best 
for particular types of issues, and in which particular health system contexts. Participation is voluntary, confidentiality assured, and anonymity 
safeguarded
• Twelve features of the policy briefs series are the focus of questions in the formative evaluation survey:
• Describes the context of the issue being addressed
• Describes different features of the problem, including (where possible) how it affects particular groups
• Describes three options for addressing the problem
• Describes key implementation considerations
• Employs systematic and transparent methods to identify, select, and assess synthesised research evidence
• Takes quality considerations into account when discussing the research evidence
• Takes local applicability considerations into account when discussing the research evidence
• Takes equity considerations into account when discussing the research evidence
• Does not conclude with particular recommendations
• Employs a graded-entry format (i.e. a list of key messages and a full report)
• Includes a reference list for those who want to read more about a particular systematic review or research study, and
• Is subject to a review by at least one policymaker, at least one stakeholder, and at least one researcher. This process is termed a merit review 
to distinguish it from a standard peer review which would typically only involve researchers in the review process
• For each design feature, the survey asks:
• How useful did they find this approach (on a scale from 1 = Worthless to 7 = Useful)?
• Are there any additional comments or suggestions for improvement?
• The survey also asks:
• How well did the policy brief achieve its purpose, namely to present the available research evidence on a high-priority issue in order to inform 
a policy dialogue where research evidence would be just one input to the discussion (on a scale from 1 = Failed to 7 = Achieved)?
• What features of the policy brief should be retained in future?
• What features of the policy brief should be changed in future?
• What key stakeholders can do better or differently to address the high-priority issue and what they personally can do better or differently?
• Their role and background 
(so that the McMaster Health Forum can determine if different groups have different views and experiences related to policy briefs)
• The Evidence-Informed Policy Networks (EVIPNet) operating in Africa, Asia and the Americas plan to use a similar approach in the formative 
evaluation of their policy briefsHealth Research Policy and Systems 2009, 7(Suppl 1):S13 http://www.health-policy-systems.com/content/7/S1/S13
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summaries of systematic reviews and overviews of system-
atic reviews)
- SUPPORT Collaboration: http://www.support-collabo
ration.org - Example of a source of policymaker-friendly
summaries of systematic reviews relevant to low- and
middleincome countries
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